top
Please input keywords
Order
*Country
한국
미국
일본
중국
영국
호주
프랑스
독일
이탈리아
싱가포르
인도
러시아
캐나다
스위스
기타 국가
*Province
*City
*Name
*Telephone
*Company
*Position
*Email
*Verification code
*Verification Code
B-hPD-1/hOX40 mice
Strain Name
C57BL/6-Pdcd1tm1(PDCD1)Bcgen Tnfrsf4tm1(TNFRSF4)Bcgen/Bcgen
Common Name  B-hPD-1/hOX40 mice
Background C57BL/6 Catalog number  120521
Related Genes 
PD-1 (Programmed death-1) ;
TNFRSF4 
(Tumor necrosis factor receptor superfamily, member 4, also known as OX40)
NCBI Gene ID
18566,22163

Protein expression analysis



Strain specific OX40 and PD-1 expression analysis in homozygous B-hPD-1/hOX40 mice by flow cytometry. Splenocytes were collected from WT and homozygous B-hPD-1/hOX40 (H/H) mice stimulated with anti-CD3ε in vivo (7.5 μg/mice), and analyzed by flow cytometry with species-specific anti-OX40 antibody. Mouse OX40 and PD-1 were exclusively detected in WT mice. Human OX40 and PD-1 were exclusively detected in homozygous B-hPD-1/hOX40 but not WT mice.


Combination therapy of PD-1(pembrolizumab) Ab and OX40 Ab


from clipboard


Antitumor activity of anti-hOX40 antibody combined with anti-hPD-1 antibody pembrolizumab in B-hPD-1/hOX40 mice. (A) Anti-hOX40 antibody combined with anti-hPD-1 antibody pembrolizumab inhibited MC38 tumor growth in B-hPD-1/hOX40 mice. Murine colon cancer MC38 cells (5×105) were subcutaneously implanted into homozygous B-hPD-1/hOX40 mice (female, 6-7 week-old, n=6). Mice were grouped when tumor volume reached approximately 150±50 mm3, at which time they were treated with anti-hOX40 antibody combined with anti-hPD-1 antibody pembrolizumab with doses and schedules indicated in panel (B) Body weight changes during treatment. As shown in panel A, combination of anti-hOX40 and anti-hPD-1 antibody shows more inhibitory effects than individual groups, demonstrating that the B-hPD-1/hOX40 mice provide a powerful preclinical model for in vivo evaluating combination therapy efficacy of hOX40 antibodies and hPD-1 antibodies . Values are expressed as mean ± SEM.

from clipboard


Antitumor activity of anti-hOX40 antibody combined with anti-hPD-1 antibody pembrolizumab in B-hPD-1/hOX40 mice. (A) Anti-hOX40 antibody combined with anti-hPD-1 antibody pembrolizumab inhibited B16-F10-hPD-L1 cells tumor growth in B-hPD-1/hOX40 mice. Murine colon cancer B16-F10-hPD-L1 cells (1×105) were subcutaneously implanted into homozygous B-hPD-1/hOX40 mice (female, 7-8 week-old, n=5). Mice were grouped when tumor volume reached approximately 150±50 mm3, at which time they were treated with anti-hOX40 antibody combined with anti-hPD-1 antibody pembrolizumab with doses and schedules indicated in panel (B) Body weight changes during treatment. As shown in panel A, combination of anti-hOX40 and anti-hPD-1 antibody shows more inhibitory effects than individual groups, demonstrating that the B-hPD-1/hOX40 mice provide a powerful preclinical model for in vivo evaluating combination therapy efficacy of hOX40 antibodies and hPD-1 antibodies . Values are expressed as mean ± SEM.